President Donald Trump signed an executive order on April 18 directing U.S. health agencies to accelerate reviews of selected psychedelic drugs. [1]
The move aims to speed access to experimental treatments for PTSD, depression and other mental‑health disorders, and to prompt a re‑examination of the drugs’ Schedule I status, which currently blocks most research. The order could speed access to experimental therapies for PTSD. Advocates say faster approval could bring decades‑old compounds into clinics within years, while families of patients see a potential lifeline. [1]
The order tasks the Food and Drug Administration, the National Institutes of Health and the Substance Abuse and Mental Health Services Administration with convening expert panels, issuing guidance within 180 days, and submitting recommendations on whether substances such as ibogaine, psilocybin and MDMA should remain classified as controlled substances. — [2]
Trump said, "directs the FDA to expedite their review of certain ..." The policy could save lives. [3]
Podcast host Joe Rogan said, "I heard about these treatments during a taping of my podcast and sent Trump some information about them." He said that growing public interest in psychedelic therapy is increasing. [3]
Industry groups and academic researchers welcomed the order, noting that faster FDA review could unlock federal grants and private investment, while critics warned that speed should not replace rigorous safety testing. The NIH has already earmarked significant funds for psychedelic studies, a boost that could double current funding levels. [2]
Republican lawmakers praised the initiative as a bold step toward medical innovation, whereas several Democratic senators called for congressional oversight to ensure that safety standards are not compromised. Both parties agreed that mental‑health crises demand new solutions. [2]
The agencies have 180 days to publish draft guidance, after which public comment periods and advisory committee meetings will shape final regulations. If the timeline holds, the first revised drug schedules could appear within a few years, opening the door for clinical trials that were previously barred. [2]
Trump’s interest in psychedelics surfaced earlier this year after a meeting with researchers and media personalities who highlighted early‑stage trial results. The president has previously dismissed unconventional therapies, making this policy shift notable. Supporters argue his personal curiosity may help break long‑standing stigma, while skeptics warn that political endorsement could outpace scientific consensus. [1]
If the FDA grants expedited pathways, pharmaceutical companies could bring psilocybin‑based antidepressants and MDMA‑assisted psychotherapy to market faster, potentially generating billions in revenue. More importantly, veterans with treatment‑resistant PTSD could gain earlier access to therapies that have shown promise in Phase III trials, reshaping the landscape of mental‑health care in the United States.
**What this means**: By leveraging executive authority, the administration is attempting to reshape federal drug policy and accelerate mental‑health innovation. If agencies follow through, patients with treatment‑resistant conditions may see new options within a few years, but the pace of review will be closely watched by safety regulators and lawmakers.
“Trump said, "directs the FDA to expedite their review of certain ..."”
By leveraging executive authority, the administration is attempting to reshape federal drug policy and accelerate mental‑health innovation. If agencies follow through, patients with treatment‑resistant conditions may see new options within a few years, but the pace of review will be closely watched by safety regulators and lawmakers.
